Innate Pharma — Regulatory Filings 2021

Jan 27, 2021

CORRESP 1 filename1.htm html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd" Document created using Wdesk Copyright 2021 Workiva Document

117 Avenue de Luminy—BP 30191 13009 Marseille, France VIA EDGAR

January 26, 2021

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: Abby Adams

Re: Innate Pharma S.A.

Registration Statement on Form F-3

Filed on January 13, 2021

File No. 333-252074

Acceleration Request

Requested Date: January 28, 2021

Requested Time: 5:00 P.M. Eastern Time

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “ Registrant ”) hereby requests that the U.S. Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form F-3 (File No. 333-252074) (the “ Registration Statement ”) to become effective on January 28, 2021, at 5:00 p.m., Eastern Time, or as soon thereafter as is practicable.

Once the Registration Statement has been declared effective, please orally confirm that event with Jeffrey Cohen of Linklaters LLP, counsel to the Registrant, at +1 (212) 903 9014. Thank you for your assistance with this matter.

[Signature Page Follows]

Sincerely, Innate Pharma S.A.
By:	/s/ Mondher Mahjoubi
	Mondher Mahjoubi Chief Executive Officer

cc: Jeffrey Cohen, Linklaters LLP

Bertrand Sénéchal, Linklaters LLP

Pierre-Emmanuel Perais, Linklaters LLP

Clément Moine, Linklaters LLP

Andy Reynolds, Linklaters LLP